5/26/2022 8:27:02 AM
CytomX Therapeutics Doses First Patient With CX-904 In Phase 1 Study In Patients With Advanced Solid Tumors
5/10/2022 4:51:59 PM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY22 Rev. Estimate To 71.1 M From 74.0 M
5/10/2022 4:51:35 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) FY22 Estimate To -1.37 From -1.75
5/10/2022 4:51:20 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q4 22 Estimate To -0.32 From -0.47
5/10/2022 4:50:37 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q3 22 Estimate To -0.35 From -0.45
5/10/2022 4:50:19 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q2 22 Estimate To -0.34 From -0.44
5/10/2022 4:49:55 PM
Wedbush Reiterates CytomX Therapeutics, Inc. (CTMX) At Outperform With $6 Down From $10 Price Target
3/3/2022 8:19:16 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) FY22 Estimate To -1.75 From -1.47
3/3/2022 8:19:01 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) Q4 22 Estimate To -0.47 From -0.40
3/3/2022 8:18:49 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) Q3 22 Estimate To -0.45 From -0.38
3/3/2022 8:18:36 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) Q2 22 Estimate To -0.44 From -0.37
3/3/2022 8:18:24 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) Q1 22 Estimate To -0.39 From -0.32
1/19/2022 8:29:54 AM
CytomX Announces FDA Clearance Of INDA For CX-904 For Treatment Of Advanced Solid Tumors
1/20/2021 9:56:15 PM
CytomX Therapeutics Prices Underwritten Public Offering Of 14.29 Mln Shares At $7.00/shr
1/19/2021 8:16:53 PM
CytomX Therapeutics Commences Underwritten Public Offering Of $75.0 Mln Of Common Stock
11/7/2018 9:22:48 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY18 Rev. Estimate To 66.5 M From 72.5 M
11/7/2018 9:21:37 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY18 Estimate To -1.68 From -1.53
5/10/2018 7:26:02 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) FY18 Rev. Estimate To 69.7 M From 74.0 M